| Tara Janae Minnix-harmon, AUD, CCC-A | |
|
508 New Hope Road, Suite #19, Princeton, WV 24740-2272 | |
| (304) 487-2487 | |
| (304) 431-3367 |
| Full Name | Tara Janae Minnix-harmon |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 13 Years |
| Location | 508 New Hope Road, Princeton, West Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962799338 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | A-0276 (West Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Princeton Audiology Clinic Inc | 1052300357 | 3 |
News Archive
Ospemifene (tradename: Senshio) is approved for the treatment of moderate to severe symptomatic vulvovaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.
PSA levels appear to be more predictive of three year prostate cancer risk in African-American men compared with Caucasian men with a family history of prostate cancer, according to a paper published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
A team of researchers of MedUni Vienna working with the endocrinologists and gender physicians Michael Leutner and Alexandra Kautzky-Willer as well the division for complex statistical systems with Peter Klimek and Caspar Matzhold in cooperation with Complexity Science Hub Vienna were able to demonstrate for the first time a connection between the potency and dosage of statins with a diagnosis of osteoporosis, based on several million data sets.
Heart failure patients with preserved ejection fraction (HFpEF) - where the heart becomes stiff and cannot relax or fill properly - did not have increased exercise tolerance after taking isosorbide mononitrate, compared to a placebo, according to a study presented today at the American Heart Association's Scientific Sessions 2015.
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
› Verified 6 days ago
| Provider Name | Princeton Audiology Clinic Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1073580817 PECOS PAC ID: 1052300357 Enrollment ID: O20040511001102 |
News Archive
Ospemifene (tradename: Senshio) is approved for the treatment of moderate to severe symptomatic vulvovaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.
PSA levels appear to be more predictive of three year prostate cancer risk in African-American men compared with Caucasian men with a family history of prostate cancer, according to a paper published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
A team of researchers of MedUni Vienna working with the endocrinologists and gender physicians Michael Leutner and Alexandra Kautzky-Willer as well the division for complex statistical systems with Peter Klimek and Caspar Matzhold in cooperation with Complexity Science Hub Vienna were able to demonstrate for the first time a connection between the potency and dosage of statins with a diagnosis of osteoporosis, based on several million data sets.
Heart failure patients with preserved ejection fraction (HFpEF) - where the heart becomes stiff and cannot relax or fill properly - did not have increased exercise tolerance after taking isosorbide mononitrate, compared to a placebo, according to a study presented today at the American Heart Association's Scientific Sessions 2015.
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tara Janae Minnix-harmon, AUD, CCC-A 508 New Hope Road, Suite #19, Princeton, WV 24740-2272 Ph: (304) 487-2487 | Tara Janae Minnix-harmon, AUD, CCC-A 508 New Hope Road, Suite #19, Princeton, WV 24740-2272 Ph: (304) 487-2487 |
News Archive
Ospemifene (tradename: Senshio) is approved for the treatment of moderate to severe symptomatic vulvovaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.
PSA levels appear to be more predictive of three year prostate cancer risk in African-American men compared with Caucasian men with a family history of prostate cancer, according to a paper published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
A team of researchers of MedUni Vienna working with the endocrinologists and gender physicians Michael Leutner and Alexandra Kautzky-Willer as well the division for complex statistical systems with Peter Klimek and Caspar Matzhold in cooperation with Complexity Science Hub Vienna were able to demonstrate for the first time a connection between the potency and dosage of statins with a diagnosis of osteoporosis, based on several million data sets.
Heart failure patients with preserved ejection fraction (HFpEF) - where the heart becomes stiff and cannot relax or fill properly - did not have increased exercise tolerance after taking isosorbide mononitrate, compared to a placebo, according to a study presented today at the American Heart Association's Scientific Sessions 2015.
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
› Verified 6 days ago
Dba Blue Ridge Hearing And Balance Clinic Audiologist Medicare: Medicare Enrolled Practice Location: 508 New Hope Road, Suite #19, Princeton, WV 24740 Phone: 304-487-2487 Fax: 304-431-3367 | |
Alan Louis Desmond, AUD CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 508 New Hope Road, Suite #19, Princeton, WV 24740 Phone: 304-487-2487 Fax: 304-431-3367 | |
Sharon Lynne Jividen, MS CCCA Audiologist Medicare: Accepting Medicare Assignments Practice Location: 508 New Hope Road, Suite #19, Princeton, WV 24740 Phone: 304-487-2487 Fax: 304-431-3367 | |
Mrs. Lindsey Shea Underwood, AU.D., CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 508 New Hope Road, Suite #19, Princeton, WV 24740 Phone: 304-487-2487 Fax: 304-431-3367 |